Asthma, characterized by respiratory symptoms and airflow restriction, requires a stepwise treatment approach for symptom reduction and exacerbation prevention. The Global Initiative for Asthma (GINA) aims to globally prevent, manage, raises awareness of asthma and providing yearly resources for healthcare providers. The 2023 GINA report provides practical pharmacological advice, including key changes in GINA strategy, recommended Inhaled Corticosteroid (ICS) dosages for different age groups. It explores the pathophysiology, historical evolution of asthma treatment, from smoke inhalation to modern inhalers, emphasizing cost and availability issues in low to middle-income countries like Nepal, Peru, and Uganda. Furthermore, the review emphasizes the role of pharmacogenomics in customizing asthma treatment based on individual genetic variations. Addressing potential side effects of ICS use, it proposes management strategies to minimize risks. This comprehensive approach aims to improve asthma control, reduce exacerbations, and enhance patient outcomes globally, while acknowledging the challenges faced in resource limited settings. Integration of pharmacogenomic data with clinical information enables tailored therapeutic strategies, advancing precision medicine in asthma care and improving patient quality of life.The review also highlights the issue of delayed specialist referrals for challenging asthma cases and offers revised guidelines for stepwise approaches to treatment across severity levels. It underscores the need for special considerations in low to middle-income countries due to limited access to inhaled medications. Overall, the review advocates a holistic approach to asthma management, combining pharmacology with genetic insights and improved healthcare delivery, to address the complexities of asthma care worldwide.

Asthma, characterized by respiratory symptoms and airflow restriction, requires a stepwise treatment approach for symptom reduction and exacerbation prevention. The Global Initiative for Asthma (GINA) aims to globally prevent, manage, raises awareness of asthma and providing yearly resources for healthcare providers. The 2023 GINA report provides practical pharmacological advice, including key changes in GINA strategy, recommended Inhaled Corticosteroid (ICS) dosages for different age groups. It explores the pathophysiology, historical evolution of asthma treatment, from smoke inhalation to modern inhalers, emphasizing cost and availability issues in low to middle-income countries like Nepal, Peru, and Uganda. Furthermore, the review emphasizes the role of pharmacogenomics in customizing asthma treatment based on individual genetic variations. Addressing potential side effects of ICS use, it proposes management strategies to minimize risks. This comprehensive approach aims to improve asthma control, reduce exacerbations, and enhance patient outcomes globally, while acknowledging the challenges faced in resource limited settings. Integration of pharmacogenomic data with clinical information enables tailored therapeutic strategies, advancing precision medicine in asthma care and improving patient quality of life.The review also highlights the issue of delayed specialist referrals for challenging asthma cases and offers revised guidelines for stepwise approaches to treatment across severity levels. It underscores the need for special considerations in low to middle-income countries due to limited access to inhaled medications. Overall, the review advocates a holistic approach to asthma management, combining pharmacology with genetic insights and improved healthcare delivery, to address the complexities of asthma care worldwide.